Immutep Limited (IMMP)
IMMPNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$3.80
+0.4600 (+13.77%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $28.01m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $2.66 to $70.60
- Average volume
- 21.2k
- Previous close
- $3.34
Analysts
1 coveringBuy1 buy, 0 hold, 0 sell
Targets a year out average $30.00, +689.5% from here
Earnings
Next report
Financials
No quarterly figures from the source.
News
8 latest- Immutep Limited - Depositary Receipt Price Target Increased by 19.55% to $80.11Fintel · 22 hours ago
- Immutep Limited Receives A$2.16 million French R&D Tax IncentiveFintel · Oct 29, 2026
- Immutep Receives A$2.16 Mln French Tax Incentive To Support Drug Development RTTNews · Oct 28, 2026
- Immutep Reports Stable Quality Of Life, Strong Tumor Fibrosis Results In Phase II Trial RTTNews · Oct 23, 2026
- Immutep Gains ARC Funding To Advance LAG-3 Studies; Stock Down 5% RTTNews · Oct 14, 2026
- Immutep Regains Nasdaq Bid Price Compliance; Stock Down RTTNews · Oct 13, 2026
- Immutep Limited - Depositary Receipt Price Target Increased by 917.93% to $69.75Fintel · Oct 2, 2026
- Immutep Post Mautre Overall Survival Data In First-Line NSCLC; Updates On TACTI-004 Analysis RTTNews · Jul 14, 2026
The company
Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- Australia and South Pacific
- Website
- immutep.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.